Sfoglia per AUTORE
CHIARA S
Collezione AO Cuneo

  

Items : 9

Prognostic and predictive role of neutrophil/lymphocytes ratio in metastatic colorectal cancer: a retrospective analysis of the TRIBE study by GONO. in Annals of oncology : official journal of the European Society for Medical Oncology / Ann Oncol. 2018 Apr 1;29(4):924-930. doi: 10.1093/annonc/mdy004.

2018
AO Cuneo
AOU Città della Salute di Torino

Santini D; Boni L; Falcone A; Tomcikova D; Tonini G; Chiara S; Di Donato S; Allegrini G; Fea E; Buonadonna A; Racca P; Tomasello G; Zaniboni A; Ronzoni M; Urbano F; Schirripa M; Marmorino F; Stellato M; Masi G; Lonardi S; Bergamo F; Zeppola T; Cremolini C; Dell'Aquila E;

Serum LDH predicts benefit from bevacizumab beyond progression in metastatic colorectal cancer. in British journal of cancer / Br J Cancer. 2017 Jan;116(3):318-323. doi: 10.1038/bjc.2016.413. Epub 2017 Jan 12.

2017
ASL Biella
AO Cuneo

Cremolini C; Falcone A; Boni L; Tomcikova D; Paris M; Bonetti A; Martignetti A; Dargenio F; Miraglio E; Amoroso D; Banzi MC; Borelli B; Chiara S; Loupakis F; Masi G; Allegrini G; Barbara C; Salvatore L; Antonuzzo L; Marmorino F;

FOLFOXIRI or FOLFOXIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: a propensity score-adjusted analysis from two randomized clinical trials. in Annals of oncology : official journal of the European Society for Medical Oncology / Ann Oncol. 2016 May;27(5):843-9. doi: 10.1093/annonc/mdw052. Epub 2016 Feb 9.

2016
AO Cuneo
AOU Città della Salute di Torino

Cremolini C; Loupakis F; Masi G; Lonardi S; Granetto C; Mancini ML; Chiara S; Moretto R; Rossini D; Vitello S; Allegrini G; Tonini G; Bergamo F; Tomasello G; Ronzoni M; Buonadonna A; Bustreo S; Barbara C; Boni L; Falcone A;

Safety and efficacy of FOLFOXIRI with or without targeted agents as first-line treatment of selected elderly metastatic colorectal cancer patients: A pooled analysis of GONO studies in Journal of Clinical Oncology

2016
AO Cuneo

Casagrande M; Moretto R; Loupakis F; Cremolini C; Masi G; Borelli B; Lonardi S; Marsico VA; Ferrari L; Ricci V; Grande R; Tomasello G; Ronzoni M; Allegrini G; Tonini G; Mancini ML; Zaniboni A; Chiara S; Carlomagno C; Falcone A;

Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYP trial. in Annals of oncology : official journal of the European Society for Medical Oncology / Ann Oncol. 2015 Apr;26(4):724-730. doi: 10.1093/annonc/mdv012. Epub 2015 Jan 18.

2015
AO Cuneo

Falcone A; Amoroso D; Bonetti A; Chiara S; Allegrini G; Boni C; Fea E; Antonuzzo L; Granetto C; Barbara C; Safina V; Cupini S; Schirripa M; Cremolini C; Fornaro L; Boni L; Masi G; Loupakis F; Salvatore L;

Real-world study of everolimus in advanced progressive neuroendocrine tumors. in The oncologist / Oncologist. 2014 Sep;19(9):966-74. doi: 10.1634/theoncologist.2014-0037. Epub 2014 Aug 12.

2014
AOU San Luigi di Orbassano
AO Cuneo

Delle Fave G; Falconi M; Colao A; Berruti A; Appetecchia M; Cartenì G; Campana D; Cassano A; Ambrosio MR; Fontana A; Pusceddu S; Spada F; Funaioli C; Antonuzzo L; Chiara S; Merlano M; Cascinu S; Pastorelli D; Faggiano A; Nobili E; Zaniboni A; Brizzi MP; Nuzzo C; Riccardi F; Tomassetti P; Lugli F; Zatelli MC; Luppi G; de Braud F; et alii...

Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer in Annals of Oncology

2014
ASL Biella
AO Cuneo
AOU Città della Salute di Torino
ASL Cuneo 2

Bajetta E; Floriani I; Di Bartolomeo M; Labianca R; Falcone A; Di Costanzo F; Comella G; Amadori D; Pinto C; Carlomagno C; Nitti D; Daniele B; Mini E; Poli D; Santoro A; Mosconi S; Casaretti R; Boni C; Pinotti G; Bidoli P; Landi L; Rosati G; Ravaioli A; Cantore M; Di Fabio F; Aitini E; Marchet A; Rulli E; Cropalato Di Tullio M; et alii...

Subgroup analyses in RAS mutant, BRAF mutant and all-wt mCRC pts treated with FOLFOXIRI plus bevacizumab (bev) or FOLFIRI plus bev in the TRIBE study in Journal of Clinical Oncology

2014
AO Cuneo

Loupakis F; Cremolini C; Lonardi S; Tomasello G; Ronzoni M; Zaniboni A; Tonini G; Valsuani C; Chiara S; Boni C; Marcucci L; Negri F; Barone C; Vitello S; D'Amico M; Granetto C; Fontanini G; Tomcikova D; Boni L; Falcone A;

Second-line chemotherapy (CT) with or without bevacizumab (BV) in metastatic colorectal cancer (mCRC) patients (pts) who progressed to a first-line treatment containing BV: Updated results of the phase III “BEBYP” trial by the Gruppo Oncologico Nord Ovest (GONO) in Journal of Clinical Oncology

2013
AO Cuneo

Masi G; Loupakis F; Salvatore L; Cremolini C; Fornaro L; Schirripa M; Granetto C; Miraglio E; Di Costanzo F; Antonuzzo L; Marcucci L; Barbara C; Boni C; Banzi M; Chiara S; Garbarino D; Valsuani C; Bonetti A; Boni L; Falcone A;